Enoticumab

Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively[1].

Product Specifications

CAS Number

[1192578-27-0]

Product Name Alternative

REGN421

UNSPSC

12352203

Target

Notch

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/enoticumab.html

Purity

99.64

Solubility

10 mM in DMSO

Smiles

[Enoticumab]

Molecular Weight

(146.48 kDa)

References & Citations

[1]Kuhnert F, Chen G, Thurston G. Potent anti-tumor activity of blocking stromal Dll4 in ovarian xenograft models[J]. Cancer Research, 2013, 73 (8_Supplement) : 5091-5091.